Neoclease

Neoclease is a biotechnology company pioneering AI-designed gene-editing therapies optimized for individual genes. Using a proprietary platform that integrates generative protein models with synthetic biology, Neoclease builds ultra-precise, delivery-ready nucleases for diseases with high unmet need. Its lead program targets LRRK2 to halt progression of Parkinson’s disease. Neoclease’s approach enables the development of editors with enhanced specificity, efficiency, and size, unlocking new possibilities across thousands of genetic diseases.